Tango Therapeutics, Inc. (TNGX)
NASDAQ:TNGX
Want to see TNGX full AI Analyst Report?
Top Page
Tango Therapeutics
(NASDAQ:TNGX)
Select Model
Select Model
Rating:58Neutral
Price Target:
$30.00
▲(12.61% Upside)
Action:Reiterated
Date:06/24/26
The score is held back primarily by weak financial performance (large losses and substantial cash burn), partially offset by a strong technical uptrend and positive corporate developments (promising early clinical data and a major financing that extends the funding runway). Valuation is a modest negative given the negative P/E and no dividend support.
Positive Factors
Strengthened funding runway
A secured ~$566.5M equity raise materially reduces near- and medium-term financing risk, giving multi-year capital to advance pivotal trials, support commercialization prep and absorb development variability. This lasting liquidity cushion improves execution optionality across R&D and go-to-market planning.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow reflects high development spending typical of late-stage biotech but creates ongoing funding dependency. Even with recent financing, large burn rates increase dilution risk if trials extend or costs rise, and constrain discretionary investments across the pipeline.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened funding runway
A secured ~$566.5M equity raise materially reduces near- and medium-term financing risk, giving multi-year capital to advance pivotal trials, support commercialization prep and absorb development variability. This lasting liquidity cushion improves execution optionality across R&D and go-to-market planning.
Read all positive factors
Tango Therapeutics (TNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.12B
Dividend YieldN/A
Average Volume (3M)4.65M
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue Growth39.04%
EPS Growth32.40%
CountryUS
Employees155
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.83
Shares Outstanding162,814,650
10 Day Avg. Volume8,047,518
30 Day Avg. Volume4,651,212
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue68.31
Enterprise Value/Gross Profit70.24
Enterprise Value/Ebitda-37.03
Forecast
1Y Price Target
$41.64Price Target Upside56.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.31
Revenue Forecast (FY)$6.06M
Tango Therapeutics Business Overview & Revenue Model
Company Description
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine meth...
How the Company Makes Money
As a clinical-stage biotechnology company, Tango Therapeutics primarily generates revenue from collaboration and licensing arrangements rather than from product sales, because it does not have broadly available commercial drugs on the market. Its ...
Tango Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.99M | 62.38M | 42.07M | 36.53M | 24.86M | 37.04M |
| Gross Profit | 55.42M | 60.10M | 42.07M | 36.53M | 24.86M | 37.04M |
| EBITDA | -105.14M | -99.31M | -127.59M | -99.19M | -106.51M | -57.05M |
| Net Income | -107.23M | -101.59M | -130.30M | -101.74M | -108.18M | -58.23M |
Balance Sheet | ||||||
| Total Assets | 435.79M | 398.69M | 316.49M | 402.57M | 436.47M | 500.15M |
| Cash, Cash Equivalents and Short-Term Investments | 379.84M | 343.14M | 257.92M | 336.88M | 366.13M | 485.25M |
| Total Debt | 32.79M | 33.57M | 36.49M | 38.92M | 41.13M | 1.50M |
| Total Liabilities | 44.29M | 52.51M | 116.97M | 149.46M | 186.99M | 155.41M |
| Stockholders Equity | 391.51M | 346.18M | 199.52M | 253.11M | 249.48M | 344.75M |
Cash Flow | ||||||
| Free Cash Flow | -142.54M | -139.93M | -132.25M | -119.51M | -116.77M | -61.36M |
| Operating Cash Flow | -141.55M | -138.89M | -131.50M | -117.98M | -109.08M | -59.53M |
| Investing Cash Flow | -61.83M | -40.87M | 86.13M | 41.43M | 26.40M | -183.43M |
| Financing Cash Flow | 302.34M | 222.50M | 47.66M | 82.41M | 1.61M | 357.32M |
Tango Therapeutics Technical Analysis
Positive
26.64
Price Trends
25.09
Positive
20.79
Positive
14.91
Positive
Market Momentum
1.95
Negative
61.64
Neutral
38.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Positive. The current price of 26.64 is below the 20-day moving average (MA) of 27.76, above the 50-day MA of 25.09, and above the 200-day MA of 14.91, indicating a bullish trend. The MACD of 1.95 indicates Negative momentum. The RSI at 61.64 is Neutral, neither overbought nor oversold. The STOCH value of 38.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNGX.
Tango Therapeutics Risk Analysis
Tango Therapeutics disclosed 78 risk factors in its most recent earnings report. Tango Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tango Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $848.05M | -4.25 | -153.61% | ― | 1.92% | -1130.30% | |
60 Neutral | $5.46B | -37.91 | -25.99% | ― | ― | 54.61% | |
58 Neutral | $5.12B | -37.92 | -41.54% | ― | 39.04% | 32.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $619.52M | -2.71 | -188.82% | ― | 4.89% | 24.20% | |
45 Neutral | $367.33M | -2.32 | -43.82% | ― | ― | ― | |
44 Neutral | $1.28B | -4.89 | -45.27% | ― | -72.09% | -754.83% |
* Healthcare Sector Average
TNGX
Tango Therapeutics
31.47
26.46
528.14%
ORKA
Oruka Therapeutics
90.60
79.52
717.69%
IMTX
Immatics
9.52
4.09
75.32%
SPRY
ARS Pharmaceuticals
8.54
-9.66
-53.08%
PRME
Prime Medicine, Inc.
3.43
1.01
41.74%
UPB
Upstream Bio, Inc.
6.75
-4.18
-38.24%
Tango Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Tango Therapeutics Adds Veteran Biopharma Leader to Board
Positive
Jun 23, 2026
On June 19, 2026, Tango Therapeutics expanded its board to seven members and appointed biopharmaceutical veteran Robert Azelby as an independent Class II director, with his term running until the 2029 annual meeting. Effective June 23, 2026, he al...
Business Operations and StrategyPrivate Placements and Financing
Tango Therapeutics Announces Major Underwritten Equity Offering
Positive
Jun 10, 2026
On June 9, 2026, Tango Therapeutics, Inc. entered into an underwriting agreement with a syndicate of banks for an underwritten offering of 18,166,667 shares of common stock and pre-funded warrants to purchase up to 1,833,395 additional shares, all...
Business Operations and Strategy
Tango Therapeutics Highlights Promising Vopimetostat Combination Data
Positive
Jun 8, 2026
On June 8, 2026, Tango Therapeutics reported positive initial safety and efficacy data from a Phase 1/2 trial of its PRMT5 inhibitor vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors in heavily pre-treated patients with MTA...
Executive/Board ChangesShareholder Meetings
Tango Therapeutics Holds 2026 Virtual Annual Stockholder Meeting
Positive
Jun 4, 2026
Tango Therapeutics held its 2026 annual meeting of stockholders in a virtual-only format on June 4, 2026, with 131,198,081 shares represented, or 90.96% of the 144,242,271 outstanding common shares entitled to vote as of the April 7, 2026 record d...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Tango Therapeutics Reshapes Board Amid Late-Stage Progress
Positive
May 13, 2026
On May 12, 2026, Tango Therapeutics announced that directors Alexis Borisy and Kanishka Pothula resigned from the board, effective May 13, 2026, with no disagreements cited over company practices. Sung Lee was appointed Lead Independent Director, ...
Executive/Board Changes
Tango Therapeutics Finalizes Separation Agreement with Former CFO
Neutral
May 8, 2026
On April 10, 2026, Tango Therapeutics’ board decided that Chief Financial Officer and principal financial officer Daniella Beckman would leave her roles, effective April 15, 2026, with her last day of employment recorded as May 1, 2026. On M...
Business Operations and StrategyExecutive/Board Changes
Tango Therapeutics Overhauls Finance Leadership Amid Clinical Push
Positive
Apr 15, 2026
On April 10, 2026, Tango Therapeutics’ board decided that Chief Financial Officer Daniella Beckman would depart her roles effective April 15, 2026, and appointed veteran biotech finance executive Matthew Gall as CFO and principal financial o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.